Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC – Get Free Report) saw a large decrease in short interest in the month of August. As of August 14th, there was short interest totaling 16 shares, a decrease of 99.8% from the July 30th total of 9,551 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 322,731 shares, the short-interest ratio is presently 0.0 days.
Oncotelic Therapeutics Price Performance
OTCMKTS:OTLC traded down $0.00 on Tuesday, reaching $0.03. 163,434 shares of the company’s stock traded hands, compared to its average volume of 172,338. The company has a quick ratio of 0.08, a current ratio of 0.08 and a debt-to-equity ratio of 0.01. The stock has a 50-day simple moving average of $0.04 and a 200-day simple moving average of $0.04. The firm has a market cap of $14.84 million, a PE ratio of 0.06 and a beta of -0.23. Oncotelic Therapeutics has a 12 month low of $0.01 and a 12 month high of $0.11.
Oncotelic Therapeutics Company Profile
Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.
Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.
See Also
- Five stocks we like better than Oncotelic Therapeutics
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Oncotelic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncotelic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
